Cross-source evidence timeline
Tesamorelin research timeline
Follow 45 selected, directly cited source records from January 19, 2010 through August 2, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Literature metadata
PubMed record PMID 41545261↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41545261 at 2026-08-10T10:49:08.747Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-01-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Regulatory
Tesamorelin DailyMed SPL version 9↗
DailyMed lists Structured Product Labeling version 9 for the reviewed Tesamorelin label family with a published date of 2026-07-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Literature metadata
PubMed record PMID 42419889↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42419889 at 2026-08-10T10:49:10.753Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-08. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Literature metadata
PubMed record PMID 22495074↗
PeptideScanner retained PubMed bibliographic metadata for PMID 22495074 at 2026-08-10T18:13:32.273Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2012-04-13. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026Clinical trials
ClinicalTrials.gov record NCT06554717↗
PeptideScanner retained ClinicalTrials.gov record NCT06554717 at 2026-07-30T16:19:36.918Z. Its registry update date was 2026-05-19, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 8, 2026Literature metadata
PubMed record PMID 34006921↗
PeptideScanner retained PubMed bibliographic metadata for PMID 34006921 at 2026-07-30T16:22:11.959Z. PubMed recorded a metadata revision date of 2026-04-07 and an Entrez history date of 2021-05-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 38905488↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38905488 at 2026-07-30T16:22:12.148Z. PubMed recorded a metadata revision date of 2026-04-01 and an Entrez history date of 2024-06-21. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Clinical trials
ClinicalTrials.gov record NCT07481734↗
PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 8, 2026Clinical trials
ClinicalTrials.gov record NCT02572323↗
PeptideScanner retained ClinicalTrials.gov record NCT02572323 at 2026-07-30T16:22:22.328Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026Literature metadata
PubMed record PMID 17571443↗
PeptideScanner retained PubMed bibliographic metadata for PMID 17571443 at 2026-07-30T16:30:45.652Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 21115997↗
PeptideScanner retained PubMed bibliographic metadata for PMID 21115997 at 2026-07-30T16:30:48.398Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2010-12-01. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 21591600↗
PeptideScanner retained PubMed bibliographic metadata for PMID 21591600 at 2026-07-30T16:30:48.420Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2011-05-20. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Regulatory
Tesamorelin DailyMed SPL version 8↗
DailyMed lists Structured Product Labeling version 8 for the reviewed Tesamorelin label family with a published date of 2026-01-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026
Source year
2025
Clinical trials
ClinicalTrials.gov record NCT03375788↗
PeptideScanner retained ClinicalTrials.gov record NCT03375788 at 2026-07-30T18:19:48.220Z. Its registry update date was 2025-11-20, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026Clinical trials
ClinicalTrials.gov record NCT03150511↗
PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026
Source year
2024
Regulatory
Tesamorelin DailyMed SPL version 7↗
DailyMed lists Structured Product Labeling version 7 for the reviewed Tesamorelin label family with a published date of 2024-12-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Regulatory
Tesamorelin DailyMed SPL version 6↗
DailyMed lists Structured Product Labeling version 6 for the reviewed Tesamorelin label family with a published date of 2024-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Regulatory
Tesamorelin DailyMed SPL version 5↗
DailyMed lists Structured Product Labeling version 5 for the reviewed Tesamorelin label family with a published date of 2024-02-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026
Source year
2022
Regulatory
Tesamorelin DailyMed SPL version 4↗
DailyMed lists Structured Product Labeling version 4 for the reviewed Tesamorelin label family with a published date of 2022-12-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT00608023↗
PeptideScanner retained ClinicalTrials.gov record NCT00608023 at 2026-07-30T19:35:26.307Z. Its registry update date was 2022-09-30, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 14, 2026
Source year
2021
Regulatory
Tesamorelin DailyMed SPL version 3↗
DailyMed lists Structured Product Labeling version 3 for the reviewed Tesamorelin label family with a published date of 2021-12-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Literature metadata
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.↗
PubMed lists PMID 25358450 in Clinical pharmacokinetics as Clinical Trial, Phase I, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2015-03 (month precision). PeptideScanner associated the retained record with the identity slug tesamorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 2015 · month precisionAdded to PeptideScanner August 13, 2026
Source year
2020
Regulatory
Tesamorelin DailyMed SPL version 2↗
DailyMed lists Structured Product Labeling version 2 for the reviewed Tesamorelin label family with a published date of 2020-04-22. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Literature metadata
PubMed record PMID 31237318↗
PeptideScanner retained PubMed bibliographic metadata for PMID 31237318 at 2026-07-30T20:30:10.504Z. PubMed recorded a metadata revision date of 2020-04-07 and an Entrez history date of 2019-06-26. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Clinical trials
ClinicalTrials.gov record NCT02196831↗
PeptideScanner retained ClinicalTrials.gov record NCT02196831 at 2026-07-30T20:33:20.623Z. Its registry update date was 2020-01-27, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026
Source year
2019
Literature metadata
PubMed record PMID 30764032↗
PeptideScanner retained PubMed bibliographic metadata for PMID 30764032 at 2026-07-30T20:44:20.588Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2019-02-16. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Regulatory
Tesamorelin DailyMed SPL version 1↗
DailyMed lists Structured Product Labeling version 1 for the reviewed Tesamorelin label family with a published date of 2019-11-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗
Added to PeptideScanner August 22, 2026Clinical trials
ClinicalTrials.gov record NCT02553603↗
PeptideScanner retained ClinicalTrials.gov record NCT02553603 at 2026-07-30T20:43:27.316Z. Its registry update date was 2019-11-04, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026Literature metadata
PubMed record PMID 19243281↗
PeptideScanner retained PubMed bibliographic metadata for PMID 19243281 at 2026-07-30T20:47:02.486Z. PubMed recorded a metadata revision date of 2019-09-17 and an Entrez history date of 2009-02-27. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026
Source year
2018
Literature metadata
PubMed record PMID 21695284↗
PeptideScanner retained PubMed bibliographic metadata for PMID 21695284 at 2026-07-30T21:09:11.482Z. PubMed recorded a metadata revision date of 2018-12-01 and an Entrez history date of 2011-06-23. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 25895899↗
PeptideScanner retained PubMed bibliographic metadata for PMID 25895899 at 2026-07-30T21:09:16.102Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2015-04-22. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 28832410↗
PeptideScanner retained PubMed bibliographic metadata for PMID 28832410 at 2026-07-30T21:09:26.816Z. PubMed recorded a metadata revision date of 2018-11-13 and an Entrez history date of 2017-08-24. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026
Source year
2017
Literature metadata
PubMed record PMID 22050344↗
PeptideScanner retained PubMed bibliographic metadata for PMID 22050344 at 2026-07-30T21:22:57.978Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2011-11-05. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 12, 2026Literature metadata
PubMed record PMID 17575575↗
PeptideScanner retained PubMed bibliographic metadata for PMID 17575575 at 2026-07-30T21:22:56.977Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2007-06-19. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 18690162↗
PeptideScanner retained PubMed bibliographic metadata for PMID 18690162 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-12. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 18724445↗
PeptideScanner retained PubMed bibliographic metadata for PMID 18724445 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-08-30. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Literature metadata
PubMed record PMID 18828236↗
PeptideScanner retained PubMed bibliographic metadata for PMID 18828236 at 2026-07-30T21:22:56.979Z. PubMed recorded a metadata revision date of 2017-11-16 and an Entrez history date of 2008-10-03. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 11, 2026Clinical trials
ClinicalTrials.gov record NCT01263717↗
PeptideScanner retained ClinicalTrials.gov record NCT01263717 at 2026-07-30T21:22:00.255Z. Its registry update date was 2017-10-30, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026
Source year
2016
Literature metadata
PubMed record PMID 27121785↗
PeptideScanner retained PubMed bibliographic metadata for PMID 27121785 at 2026-07-30T21:38:23.144Z. PubMed recorded a metadata revision date of 2016-04-28 and an Entrez history date of 2016-04-29. PeptideScanner associated this retained record with the identity slug tesamorelin. These dates describe PubMed metadata history, not the article's original publication date.↗
Added to PeptideScanner August 10, 2026
Source year
2013
Clinical trials
ClinicalTrials.gov record NCT02012556↗
PeptideScanner retained ClinicalTrials.gov record NCT02012556 at 2026-07-30T21:55:56.632Z. Its registry update date was 2013-12-16, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner September 9, 2026
Source year
2012
Regulatory
Federal Register notice 2012-10808↗
The Federal Register published notice 2012-10808, attributed to FDA and its parent HHS department, on 2012-05-04. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.↗
Added to PeptideScanner August 21, 2026
Source year
2011
Clinical trials
ClinicalTrials.gov record NCT00850564↗
PeptideScanner retained ClinicalTrials.gov record NCT00850564 at 2026-07-30T22:15:58.888Z. Its registry update date was 2011-04-19, and PeptideScanner's reviewed identity mapping was tesamorelin.↗
Added to PeptideScanner August 9, 2026
Source year
2010
Regulatory
Drugs@FDA application BLA022505↗
The official Drugs@FDA dataset lists original submission 1 for BLA 022505 with status AP dated 2010-11-10, and names tesamorelin acetate among the application record's active ingredients.↗
Added to PeptideScanner August 14, 2026Regulatory
Federal Register notice 2010-6169↗
The Federal Register published notice 2010-6169, attributed to FDA and its parent HHS department, on 2010-03-22. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.↗
Added to PeptideScanner August 21, 2026Regulatory
Federal Register notice 2010-785↗
The Federal Register published notice 2010-785, attributed to FDA and its parent HHS department, on 2010-01-19. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Tesamorelin.↗
Added to PeptideScanner August 21, 2026